Please use a PC Browser to access Register-Tadawul
Get It
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views
Axsome Therapeutics, Inc. -1.01%
Axsome Therapeutics, Inc. AXSM | 0.00 |
Ratings for Axsome Therapeutics (NASDAQ:AXSM) were provided by 31 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 18 | 13 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 3 | 3 | 0 | 0 | 0 |
| 2M Ago | 10 | 8 | 0 | 0 | 0 |
| 3M Ago | 5 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $168.71, along with a high estimate of $216.00 and a low estimate of $122.00. Marking an increase of 9.04%, the current average surpasses the previous average price target of $154.73.
Decoding Analyst Ratings: A Detailed Look
The standing of Axsome Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Graig Suvannavejh | Mizuho | Raises | Outperform | $216.00 | $212.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $200.00 | $200.00 |
| Ami Fadia | Needham | Maintains | Buy | $153.00 | $153.00 |
| Joel Beatty | Baird | Raises | Outperform | $160.00 | $132.00 |
| Vikram Purohit | Morgan Stanley | Raises | Overweight | $190.00 | $125.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $212.00 | $195.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $200.00 | $200.00 |
| Ami Fadia | Needham | Maintains | Buy | $153.00 | $153.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $200.00 | $190.00 |
| Joon Lee | Truist Securities | Raises | Buy | $200.00 | $190.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $192.00 | $143.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $153.00 | $153.00 |
| Ami Fadia | Needham | Raises | Buy | $153.00 | $133.00 |
| Cerena Chen | Wells Fargo | Raises | Overweight | $160.00 | $140.00 |
| David Hoang | Deutsche Bank | Announces | Buy | $176.00 | - |
| Jason Gerberry | B of A Securities | Raises | Buy | $167.00 | $143.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $195.00 | $137.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
| Marc Goodman | Leerink Partners | Raises | Outperform | $150.00 | $110.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $137.00 | $122.00 |
| Joon Lee | Truist Securities | Raises | Buy | $190.00 | $180.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $143.00 | $139.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $190.00 | $180.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $139.00 | $139.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $180.00 | $180.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Joon Lee | Truist Securities | Raises | Buy | $180.00 | $150.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Graig Suvannavejh | Mizuho | Lowers | Outperform | $122.00 | $124.00 |
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axsome Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Axsome Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Axsome Therapeutics analyst ratings.
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Financial Milestones: Axsome Therapeutics's Journey
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 66.04%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -63.08%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -99.94%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Axsome Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -13.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 3.38. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
The Core of Analyst Ratings: What Every Investor Should Know
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.